Abstract 37P
Background
Atypical Ductal Hyperplasia (ADH) is a pre-malignant high-risk breast lesion, with morphological features similar to that of ductal carcinoma in situ (DCIS). The WHO diagnosis of ADH is defined as cytonuclear and architectural atypia <2mm in size. The current standard management is surgical excision, due to its reported 10-30% risk of upgrade to breast cancer. However, an increasingly observed alternative management utilizes a conservative approach with annual radiological follow up, quoting lower upgrade risks of 3-5%. Indications for conservative follow-up include low-risk patients or intial biopsy with vacuum assistance. Our primary aim is to investigate the ADH upgrade risk in a Singapore cohort, with a secondary goal of comparing upgrade cancer rates in upfront surgical management versus upgrade rates on conservative surveillance, to discuss feasibility of adopting a primarily conservative approach for the population.
Methods
A retrospective study was performed of 221 patients diagnosed with ADH between January 2013 to June 2023 in a tertiary institute. Initial biopsy histology, management approach and patient outcomes were evaluated. Outcome was measured by upgrade to early breast cancer. Odds ratio & relative risk was used to adjust for demographics, risk profile and biopsy methods.
Results
221 patients were diagnosed with ADH on biopsy, of whom 8 opted for surveillance. There was an overall upgrade risk of 31.22%, with 75.36% of upgrade histology being DCIS. Of all upgrades, 97.10% were diagnosed on upfront surgical excision after a mean period of 39 days, while 2.9% were diagnosed after a period of conservative surveillance. Of the 8 patients opting for conservative management, 1 patient received repeat biopsy and another 2 patients received surgical excision after a mean period of 268 days.
Conclusions
Our findings of a 31% upgrade risk of ADH to early breast cancer, consistent with that of reported literature, still support the case for upfront surgical excision of ADH. We recommend upfront surgical excision of ADH once discovered on initial biopsy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract